ArticlePloS one2026
The epidemiology of the viral hepatitis in Brazil: A scoping review.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrazil has advanced toward eliminating viral hepatitis by 2030 through broad prevention, diagnosis, and treatment policies. Yet substantial gaps persist across the care continuum, especially in vulnerable populations and underserved regions. This scoping review synthesizes nationwide epidemiologic patterns and identifies knowledge gaps to inform policy.
methodsWe conducted a PRISMA‑guided scoping review on seven databases (2013-2024) for Portuguese/Spanish/English observational studies or systematic reviews with post‑2010 data, extracting epidemiological patterns by viral hepatitis type and population group.
resultsAcross 200 included studies, the combined sample encompassed more than 14.5 million individuals. Hepatitis B was the most studied, followed by hepatitis C. Hepatitis A seroprevalence in general population ranged from 33.3-67.8%. In vulnerable populations, highest seroprevalence was among incarcerated populations (88.1%), followed by immigrants (87.4%) and transgender individuals (75.6%). Hepatitis B presented HBsAg prevalence ranging from 0-7.5% in the general population, with the highest rates in an endemic Amazon region. Hepatitis C seroprevalence varied from 0.04-2.2% in the general population, with higher rates among people who use drugs (36.9%). Hepatitis D was predominantly reported in the Amazon region, with prevalence ranging from 0-23.9%. For hepatitis E, prevalence in the general population ranged from 0.9-59.4%, with the highest value in the South region.
conclusionsViral hepatitis in Brazil shows heterogeneous epidemiologic patterns across regions and populations, alongside unequal research output. The predominance of small, cross‑sectional studies and their limited integration with social determinants of health highlight the need for future research employing methodologies that address the gaps identified in this review. The resulting evidence map can guide policies aligned with national elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.